CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
6 reports, 4 independent
Updated Thu 00:00
No new developments lately
- Reports
- 6
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CMS began negotiating drug prices for AstraZeneca and Bristol-Myers Squibb drugs.1 source
Market performance diverges based on outlooks, and an agreement was reached to provide Eliquis free to the program.1 source
- Major pharmaceutical companies are part of the ten largest global pharma giants as the industry seeks to weaken drug price negotiation.Sub-event
CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.
- Ford proposes capping prescription drug prices negotiated by Medicare and filed lawsuits against Biden and Trump.
- CMS finalized Medicare changes for 2027, noting that Medicare cost limits are outpacing Social Security COLA increases.
- Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.